Clinuvel Pharmaceuticals Plans to Report Late-Stage Vitiligo Study Topline Results in December

MT Newswires Live08:38

Clinuvel Pharmaceuticals (ASX:CUV) is completing its first late-stage study of Scenesse in vitiligo, a condition that causes the loss of skin color, and expects to report topline results in December, according to a Tuesday filing with the Australian bourse.

The trial has enrolled 210 patients globally, and its primary endpoint focuses on the proportion of patients who achieve a total body surface area response of equal to or greater than 50%, per the filing.

The late-stage trial will be followed by a registration study that is expected to start in November, with a 12-month recruitment period planned, the company said.

Clinuvel shares gained 1% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment